Ask a Question

You visited our site and still have questions? Feel free to contact us

Consultation and guidance given not in the framework of service does not serve as a replacement for a physician’s examination or consultation, and is not considered a “medical diagnosis” or “medical opinion". In all cases of urgency, distress or emergency (physical and/or mental), seek medical care with a family doctor, closest emergency room, and/or ambulatory service.   

Start service


Terms of use

Medix FTP Service (the "Service") is designed to provide you with an easy way to transfer files relevant to the management of your case to Medix Medical Services Europe Limited ("Medix", "we" and "us").


The following terms and conditions together with the Medix Information Security Policy (which may be found at http://medix- (together, the "Terms of Service"), form the agreement between you and us in relation to your use of the Service. You should read the Terms of Service carefully before agreeing to them. If you do not understand any part of the Terms of Services, then please contact us at for further information. You acknowledge and agree that by clicking on the "Upload" button, you are indicating that you accept the Terms of Services and agree to be bound by them.


Using the Service


In order to use the Service, you will be required to log in by submitting your member number which was provided to you by the Medix staff, your name and e-mail address. Once you have logged in, you will be able to upload files to the Service. We will download your files to our system and no copy will be retained on the server used to provide the Service. For detailed upload instructions, please click here.


Protection of your information


We take the safeguarding of your information very seriously. In order to prevent unauthorised access or disclosure of your information we have put in place appropriate physical, electronic and administrative procedures to safeguard and secure the files you upload to the Service. However, no method of transmission over the internet, or method of electronic data storage is 100% secure and while we have put in place appropriate protections, we cannot guarantee the security of information you upload to the Service.


Quality and availability of the Service


While we make reasonable efforts to provide the Service, it is provided "as is" with no representation, guarantee or warranty of any kind as to its availability, functionality, that it will meet your requirements or that it will be free of errors or viruses.


We will not be responsible for any damage to your computer system or the computer system of any third party resulting from your use of the Services where such damage is caused by circumstances which are beyond our reasonable control.


I agree
Start service
Start service
HomeTestimonials Change of TreatmentGenetic Targeting - Personalised Care

Genetic Targeting - Personalised Care

Tobacco smoking is by far the leading cause of lung cancer, attributing to 80% of lung cancer cases and is also responsible for a multitude of others as a result of exposure to secondhand smoke.

However, not all people suffering from lung cancer have a history of smoking. For the most part, non-smokers diagnosed with lung cancer have a certain genetic mutation which is the main cause of the disease. This has led to advancements in new specialised drug treatments aimed at targeting specific genetic mutations to treat patients effectively.


Mr. J is one such patient, who was diagnosed with stage 3 cancer at the age of 42. He completed a course of chemotherapy, the standard treatment for his disease. However, despite the rigorous treatment regimen, the cancer progressed to stage 4 metastatic lung cancer in under a year.


Metastatic cancer develops when the cells of a cancerous tumour invade tissues in other locations than their original organ. If the cells reach the bloodstream or the lymphatic system, the cancer may spread throughout the body. The origin of the cells determines the type of cancer, while specific genetic mutations that the cancer expresses can indicate suitable treatment strategies.


Mr. J's treating physicians commenced systemic treatment with Gefitinib, a common drug for metastatic lung cancer, and a targeted therapy known to work for certain patients with an EGFR mutated gene, but it had limited effect, and Mr. J’s disease continued to progress as his chances for survival deteriorated.



In the hopes of finding a more effective treatment strategy, Mr. J contacted Medix. Medix appointed a dedicated Personal Medical Case team for Mr. J and with his consent, Medix retrieved all his clinical records, including imaging and molecular analysis, and sent them to a world-renowned oncologist, specialised in the treatment of lung cancer.


The consultant’s aim was to examine how to adapt and personalised Mr. J's systemic treatment more precisely to his condition. He carefully reexamined the disease progression as well as the molecular analysis and discovered that the targeted therapy that was given to Mr. J initially did not suit his genetic mutation, as Mr. J presented with BRAF mutation which is not the target of Gefitinib. Since the treatment was not fit for Mr. J’s specific cancer mutation, it had a very limited effect.


Medix’ consultant oncologist advised Mr. J to adopt a target-specific therapy that was aimed precisely for the BARF mutation his cancer displayed. He did so by introducing Mr. J to a relatively new treatment which was not offered previously, a combination targeted therapy of Dabrafenib and Trametinib, which was in the stages of advanced clinical trials. The suggested treatment, although relatively new, had already shown much better results in recent clinical trials among patient who presented with BRAF mutation and metastatic lung cancer.


The consulting oncologist recommended that Mr. J enroll in a clinical trial using the mentioned combined targeted therapy. Subsequently, Medix’ Research Team had found that an international trial was active and introduced Mr. J to a local national cancer centre that participated in the trial, allowing access to the treatment and clinical trial.


In retrospect, Mr. J was disappointed that his initial treating doctors, although highly regarded, were unable to devise a treatment strategy that addressed his personal needs effectively.



Mr. J continues to show remarkable improvement since commencing the clinical trial. He is extremely grateful for Medix' guidance and support during this difficult time and is utterly impressed by the level of expertise, global reach, and breadth of medical knowledge coupled with unwavering determination to find a viable treatment plan to save his life.  

By continuing to use this site you consent to the use of cookies on your device as described in our cookie policy unless you have disabled them. You can change your cookie settings at any time but parts of our site will not function correctly without them.